Hepatitis C News and Research

Latest Hepatitis C News and Research

Johns Hopkins student receives 2014 Excellence in Public Health Award

Ramy El-Diwany, a fifth-year M.D./Ph.D. student at the Johns Hopkins University School of Medicine, has won a 2014 Excellence in Public Health Award from the U.S. Public Health Service (USPHS) Physician Professional Advisory Committee for his contributions to community health services.

10 Apr 2014

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection.

10 Apr 2014

Small financial incentives can improve people’s completion of HBV vaccination, study finds

Small financial incentives, totalling as little as £30, can dramatically increase the likelihood of people who inject drugs completing a course of hepatitis B virus (HBV) vaccination, according to new research published in The Lancet.

10 Apr 2014

Portrait of newly insured takes shape

Early enrollees in the health law's marketplaces were more likely to use expensive specialty drugs and less likely to use contraceptives, according to an analysis of two months of drug claims data by Express Scripts. A Rand analysis, meanwhile, argues that most of the newly insured signed up with an employer rather than buying it through the marketplaces.

10 Apr 2014

First Edition: April 9, 2014

Today's headlines include coverage of the release of Medicare billing and utilization data, as well as early insights into who enrolled in health coverage as a result of the health law.

9 Apr 2014

EASL to present online HCV management recommendations at the ILCTM

The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress- (ILC).

9 Apr 2014

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor.

8 Apr 2014

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.

3 Apr 2014

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.

3 Apr 2014

Drinking two or more cups of coffee each day reduces risk of death from liver cirrhosis by 66%

New research reveals that consuming two or more cups of coffee each day reduces the risk of death from liver cirrhosis by 66%, specifically cirrhosis caused by non-viral hepatitis. Findings in Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, show that tea, fruit juice, and soft drink consumption are not linked to cirrhosis mortality risk. As with previous studies heavy alcohol use was found to increase risk of death from cirrhosis.

2 Apr 2014

ABL enters into licensing agreement with CRP-Santé for COMET software

Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based company today announced that it has entered into an exclusive worldwide licensing agreement with CRP-Santé, a Luxembourg-based public research center active in the field of clinically oriented biomedical research, for its COMET (COntext-based Modeling for Expeditious Typing) software, a tool designed to rapidly analyze and optimally subtype large genetic data sets arising from epidemiological or antiretroviral resistance in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) fields.

2 Apr 2014

Expensive hepatitis drug draws huge sales

The demand for Gilead Sciences' Sovaldi, which costs $1,000 a pill, indicates how hard it is for insurers to curb the use of life-saving medicines. Meanwhile Humana names a former Goldman Sachs executive as finance chief.

2 Apr 2014

First Edition: April 1, 2014

Today's early morning highlights from the major news organizations, including an array of stories as the health law's enrollment period comes to a close

1 Apr 2014

Safer sharps: an interview with Paul Lindsell, Managing Director, MindMetre

In 2010, the European Council described sharps injuries as one of the most serious health and safety threats in European workplaces as an estimated one million injuries were occurring each year.

1 Apr 2014

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.

29 Mar 2014

Viewpoints: Nothing 'magical' about 6 million enrollees; the high cost of hep C medicine

Big news this afternoon on the Affordable Care Act: The ACA exchange signups have reached the 6 million mark. With a few more days to go before the open sign-up period closes (well, sort of) it looks like the original 7 million estimate -- which the Congressional Budget Office had revised downward after the botched October roll-out of the federal exchange -- is going to be pretty close to the mark.

29 Mar 2014

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy - delivered directly through a tumor's blood supply - is working.

27 Mar 2014

Inovio Pharmaceuticals receives three industry awards at World Vaccine Congress

Inovio Pharmaceuticals, Inc. today announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.

26 Mar 2014

HIV and Hepatitis C vaccines now closer to reality

Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research.

26 Mar 2014

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

Two grants from the National Institutes of Health will allow Saint Louis University researchers to build on breakthroughs in understanding the hepatitis B virus and begin the search for a drug to cure - not just halt - the illness.

26 Mar 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Johns Hopkins student receives 2014 Excellence in Public Health Award

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Small financial incentives can improve people’s completion of HBV vaccination, study finds

Portrait of newly insured takes shape

First Edition: April 9, 2014

EASL to present online HCV management recommendations at the ILCTM

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Drinking two or more cups of coffee each day reduces risk of death from liver cirrhosis by 66%

ABL enters into licensing agreement with CRP-Santé for COMET software

Expensive hepatitis drug draws huge sales

First Edition: April 1, 2014

Safer sharps: an interview with Paul Lindsell, Managing Director, MindMetre

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

Viewpoints: Nothing 'magical' about 6 million enrollees; the high cost of hep C medicine

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

Inovio Pharmaceuticals receives three industry awards at World Vaccine Congress

HIV and Hepatitis C vaccines now closer to reality

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Hepatitis C News and Research

Latest Hepatitis C News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in